Type of antibody:
Primary antibodies
recombinant human IgG1
Alternative names:
SIGLEC-2, B-lymphocyte cell adhesion molecule (BL-CAM), Sialic acid-binding Ig-like lectin 2 (Siglec-2)

Specifications for CD22 antibodies


Clone REA340 recognizes the human CD22 antigen, a single-pass type I membrane protein which is also known as sialic acid-binding Ig-like lectin 2 (Siglec-2). In peripheral blood, cell surface expression of CD22 is found on mature B cells, but is lost during terminal differentiation to plasma cells. In bone marrow, surface expression of CD22 can be detected from the pre–B cell stage on. Cytoplasmic expression of CD22 can also be found in late pro–B cells and early–B cells. CD22 plays a strong role in cell interactions and B cell activation. It is a regulatory molecule that prevents the overactivation of the immune system and the development of autoimmune diseases. CD22 has emerged as an ideal target for monoclonal antibody based therapy of B cell malignancies including most lymphomas and many leukemias.
Additional information: Clone REA340 displays negligible binding to Fc receptors.

Alternative names

SIGLEC-2, B-lymphocyte cell adhesion molecule (BL-CAM), Sialic acid-binding Ig-like lectin 2 (Siglec-2)

Detailed product information

Technical specifications

Isotyperecombinant human IgG1
Type of antibodyPrimary antibodies
Alternative names of antigenSIGLEC-2, B-lymphocyte cell adhesion molecule (BL-CAM), Sialic acid-binding Ig-like lectin 2 (Siglec-2)
Molecular mass of antigen [kDa]93
Distribution of antigenB cells

Resources for CD22 antibodies


Please follow this
to search for Certificates of Analysis (CoA) by lot number.

References for CD22 antibodies


  1. Stamenkovic, I. et al. (1990) The B-cell antigen CD22 mediates monocyte and erythrocyte adhesion. Nature 345(6270): 74-77
  2. Wilson, G. L. et al. (1991) cDNA cloning of the B cell membrane protein CD22: a mediator of B-B cell interactions. J. Exp. Med. 173(1): 137-146
  3. Stelzer, G. T. et al. (1997) U.S.-Canadian consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: standardization and validation of laboratory procedures. Cytometry 30(5): 214-230
  4. Rothe, G et al. (2012) Consensus protocol for the flow cytometric Immunophenotyping of hematopoietic malignancies. Leukemia 10(5): 877-895
  5. van Dongen, J. J. M. et al. (2012) EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia 26(9): 1908-1975
  6. Sullivan-Chang, L. et al. (2013) Targeting CD22 in B-cell malignancies: current status and clinical outlook. BioDrugs 27(4): 293-304
  7. Clinical and Laboratory Standards Institute (CLSI) (2007) Clinical Flow Cytometric Analysis of Neoplastic Hematolympoid Cells, CLSI document H43-A2 (ISBN 1-56238-635-2). CLSI; Approved Guideline - Second Edition
  8. Clinical and Laboratory Standards Institute (CLSI) (2007) Enumeration of immunologically defined cell populations by flow cytometry, CLSI document H42-A2 (ISBN 1-56238-640-9). CLSI; Approved Guideline - Second Edition

Seems like you are coming from USA!
Do you want to visit our website in your country?